IN8bio logo

IN8bio

Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease

25 employees · est. 2016 · New York, United States

VS
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc.

Pioneering a Multi-Antigen Approach

20 employees · est. 2018 · Houston, United States

IN8bio is the older company (2016 vs 2018).

Side-by-Side Comparison

IN8bio Marker Therapeutics, Inc.
Founded
2016 older 2018
Headquarters
New York, United States Houston, United States
Employees
25 20
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health and Wellness
Funding Stage
Unknown Grant
Total Funding
$209.96M $98.60M
Funding Rounds
8 5
Services
Not tracked yet Development of Multi-Antigen Recognizing (MAR) T cell therapies, Clinical trials for novel therapies, Research and development in immunotherapy
Target Customers
Not tracked yet Patients with lymphoma, Individuals with blood cancers, Patients with solid tumors, Healthcare providers, Medical researchers
Taxonomy
Not tracked yet Immuno-Oncology, T Cell-based Immunotherapies, Hematological Malignancies, Solid Tumor Indications, Multi-antigen Approach, Non-engineered T Cells, Tumor-associated Antigens, Cell Therapy Technology, Cost-effective Manufacturing, Reduced Toxicity, Clinical-stage Company, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Adoptive T Cell Therapy
Website
in8bio.com markertherapeutics.com
IN8bio logo

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. The company leverages its expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific ma...

Marker Therapeutics, Inc. logo

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., founded in 2018, is making significant strides in the fields of Biotechnology and Health and Wellness. Headquartered in the United States, the company is driven by the slogan "Pioneering a Multi-Antigen Approach," focusing on the development of advanced T cell-based immuno...

We will tell you when either one moves

BounceWatch watches IN8bio and Marker Therapeutics, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at IN8bio and Marker Therapeutics, I... — by email.

Frequently Asked Questions

IN8bio — Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease. Marker Therapeutics, Inc. — Pioneering a Multi-Antigen Approach. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
IN8bio has raised $209.96M while Marker Therapeutics, Inc. has raised $98.60M.
IN8bio and Marker Therapeutics, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare IN8bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at IN8bio on 9 Jun 2026, and Marker Therapeutics, Inc. on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy